RADNOSTIX INC (INIS) Form 10-Q — May 20, 2026
Radnostix Inc. reported a 27% year-over-year revenue decline to $2.38 million for Q1 2026, driven by voluntary recalls of its Generic Sodium Iodide I-131 and Dibasic Sodium Phosphate Capsules, as well as a shutdown of its Cobalt-60 manufacturing hot cells for rehabilitation. The company posted a net loss of $1.35 million, significantly worse than the $112,694 loss in the prior year period, exacerbated by a $102,441 out-of-period accounting adjustment for stock-based compensation and increased operating expenses.
Key figures
- Revenue
- 2378924
- Total Debt
- 14541527
- Revenue Yoy
- -27
- Cash Position
- 1347394
- Gross Profit
- 1150948
- Operating Expenses
- 2460980
- Shares Outstanding
- 529130353
- Duf6 Asset Sale Value
- 12500000
- Out Of Period Adjustment
- 102441
- Stock Based Compensation
- 244059
- Series CPreferred Dividends
- 243780
Price after filing
Close on the filing date to close N calendar days later (from $0.08). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.